SuperLife High Growth

SuperLife High Growth has placed 2nd in its category over five years, a standout result for a fund managing $785 million across more than 20,000 members. It charges 0.63% annually in total fees, including a small performance fee component.

The portfolio allocates 95% to growth assets, with international shares commanding nearly two-thirds of the fund at 65.5%. Australasian shares take 23%, while listed property and infrastructure holdings add just over 10% combined. The top holdings reveal a distinctive tilt: alongside the expected US technology giants such as NVIDIA (3.3%), Apple (3%) and Microsoft (2.1%), the fund has placed significant weight in thematic ETFs covering global infrastructure and property, each around 5%. Emerging markets feature through both a Vanguard ETF (4.5%) and an ESG-screened allocation (2.4%). Fisher & Paykel Healthcare is the sole New Zealand name in the top ten, at just under 2%.

The fund has delivered 14.2% over one year and 15.4% annualised over three years, placing it 7th and 6th respectively within the aggressive category. Its five-year return of 9.4% annualised reflects a longer view through varied market conditions. At risk level 6, this is a high-growth structure built for extended investment horizons.

General information only, not financial advice. Past performance is not a reliable indicator of future results.